Navigation Links
California Healthcare Institute Appoints Allergan CEO Chairman of the Board, Elects New Board Members

La Jolla, Calif. (PRWEB) January 22, 2013

CHI-California Healthcare Institute announced today the election of David E.I. Pyott, chairman of the board, president and chief executive officer of Allergan, Inc., to serve as chairman of the CHI board of directors. CHI’s board also elected two new members: Richard J. Gregory, Ph.D., who serves as senior vice president and head of R&D for the Sanofi-Genzyme R&D Center, and Joshua J. Ofman, M.D., M.S.H.S., who serves as senior vice president of Global Value, Access and Policy for Amgen. CHI is a non-profit public policy research organization, representing leading California academic institutions, biotechnology, medical device, diagnostics and pharmaceutical firms.

“These veteran industry executives will help guide CHI’s approach to the important issues facing the biomedical community today,” said David L. Gollaher, Ph.D., CHI president and CEO. “From coverage and reimbursement to government funding of basic research, CHI’s leadership will be focused on advancing a policy agenda that helps sustain and strengthen California’s life sciences ecosystem.”

Pyott was elected to the CHI board in 1998, serving as its chairman in 2003-04. During his chairmanship, he was instrumental in strengthening CHI’s board and the organization’s financial position as well as focusing its political agenda in Washington and Sacramento.

Pyott joined Allergan in January 1998 as president and CEO and has transformed Allergan from a small eye care business to a global specialty pharmaceutical and medical device company with leadership positions in six medical specialties. In 2006, Pyott was bestowed with the honor of Commander of the Most Excellent Order of the British Empire (CBE) by Her Majesty the Queen in acknowledgement of his contribution to British business excellence and management skills in the United States. He was also recognized by Harvard Business Review as one of “The 100 Best-Performing CEOs in the World” in both 2009 (ranked #50) and 2013 (ranked #26) and was recognized as the “No. 1 CEO in Specialty Pharmaceuticals” by Institutional Investor magazine in 2005, 2007, and 2012. In 2010, he received an honorary degree, the UCI Medal, and the Moacyr Gold Medal for services to Brazilian ophthalmology. He holds a law degree from the Europa Institute at the University of Amsterdam, a master’s degree from the University of Edinburgh, and a master of business administration from the London Business School.

Pyott replaces outgoing CHI Chairman Carl Hull, senior vice president and general manager of diagnostics at Hologic + Gen-Probe Inc. Hull served as chairman from 2011-2012 and has been a dedicated board member since July 2009.

Gregory joined Genzyme Corporation, a Sanofi company, in 1989, where he was responsible for a number of discovery projects in the molecular biology department. In 1990, his group at Genzyme was the first to express the cystic fibrosis transmembrane conductance regulator (CFTR) and to determine the molecular defect caused by the most common mutation of CFTR. This research on the molecular basis of cystic fibrosis led to the development of Genzyme’s CF gene therapy program, for which Gregory was project team leader until 1993. From 1993 to 1995, he served as director of molecular biology at Canji, Inc. in San Diego, where he developed therapeutics based on tumor suppressor genes. Gregory returned to Genzyme in 1995 to head the gene therapy program as vice president. In 2003, Gregory was appointed head of research for Genzyme, where he was responsible for early R&D, from discovery to development, in all therapeutic areas. In 2011, following the acquisition of Genzyme by Sanofi, Gregory was appointed head of the Sanofi-Genzyme R&D Center. In his current role, he is responsible for R&D, from discovery through proof of concept in man, in a wide range of therapeutic areas, including rare diseases, immune disorders and tissue protection/regenerative medicine. He received his doctorate in biochemistry from the University of Massachusetts at Amherst in 1986, followed by post-doctoral research in cancer genetics at the Worcester Foundation for Experimental Biology in Shrewsbury, Mass.

Ofman is responsible for directing Amgen activities related to ensuring that Amgen products have a compelling value proposition and obtain market access from payers in each market, worldwide. These activities include global pricing, market access planning, global health economics, international government affairs, and health policy. Prior to joining Amgen in 2003 as head of U.S. Health Economics and Outcomes Research, Ofman was a member of the academic faculty in the Department of Medicine and Health Services Research, UCLA School of Medicine, Cedars-Sinai Medical Center. In this capacity, Ofman worked extensively with the Agency for Healthcare Research and Quality’s Southern California Evidence-Based Practice Center and taught courses on the principles of evidence-based medicine. Ofman also served as the senior vice president of Zynx Health Inc., a consulting company focused on evidence-based clinical information for quality improvement, and reimbursement and health economics strategy for life sciences companies. Ofman received his undergraduate degree in the history and philosophy of science at University of California, Berkeley before completing his medical education at UC Irvine School of Medicine. Following an internship and residency in internal medicine at UCLA Medical Center residency, Ofman completed a two-year VA/UCLA/RAND fellowship in health services research, during which time he received his Masters of Science in Health Services (MSHS) degree from the UCLA School of Public Health.

About CHI
CHI represents more than 275 leading biotechnology, medical device, diagnostics, and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is Follow us on Twitter @calhealthcare, Facebook, LinkedIn and YouTube.

Editorial note: photos available on request.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Synteract and MediciNova Partner in "Fight For Air Walk" to Support the American Lung Association in California
2. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
3. Epitomics, Inc. and University of California, Davis, Complete Star Program for High-Throughput Measurement of Antibody-Antigen Interactions
4. Agendia Signs Contract with Blue Shield of California
5. Intellect Neurosciences Enters Collaboration Agreement with Leading Alzheimers Research Group at University of California Irvine to Test First in Class Dual Target Vaccine
6. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
7. Pacific BioStorage Announces an Exciting New First for The Life Sciences Industry in Southern California
8. Lightning Brewery’s Craft Beer Old Tempestuous Ale Wins Best of Show at 2012 California State Fair Commercial Brewing Competition
9. Californians Take One Step Closer to Directly Accessing Physical Therapy Services for Immediate Treatment
10. California Healthcare Institute Issues Statement on Supreme Court Ruling on the Affordable Care Act
11. California Physical Therapists Prediction Proved "Right" by Results of State Board Audit
Post Your Comments:
(Date:11/24/2015)... ... 24, 2015 , ... The United States Golf Association (USGA) today announced Dr. ... Award. Presented annually since 1961, the USGA Green Section Award recognizes an individual’s distinguished ... , Clarke, of Iselin, N.J., is an extension specialist of turfgrass pathology in ...
(Date:11/24/2015)... , Nov. 24, 2015 Halozyme Therapeutics, Inc. (NASDAQ: ... Conference in New York on Wednesday, December ... Helen Torley , president and CEO, will provide a corporate overview. ... New York at 1:00 p.m. ET/10:00 a.m. PT . ... investor relations, will provide a corporate overview. --> th ...
(Date:11/24/2015)... ... November 24, 2015 , ... Copper is an essential ... bound to proteins, copper is also toxic to cells. With a $1.3 million ... (WPI) will conduct a systematic study of copper in the bacteria Pseudomonas aeruginosa ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ - ... the request of IIROC on behalf of the Toronto ... this news release there are no corporate developments that ... price. --> --> ... --> . --> Aeterna Zentaris ...
Breaking Biology Technology:
(Date:11/26/2015)... -- Research and Markets ( ) has announced ... Technology and Patent Infringement Risk Analysis" report to ... --> Fingerprint sensors using capacitive technology represent a ... vendor Idex forecasts an increase of 360% of the ... of the fingerprint sensor market between 2014 and 2017 ...
(Date:11/20/2015)... 2015 NXTD ) ("NXT-ID" or ... growing mobile commerce market and creator of the Wocket® ... was recently interviewed on The RedChip Money Report ... weekend on Bloomberg Europe , Bloomberg Asia, Bloomberg ... NXTD ) ("NXT-ID" or the "Company"), a biometric ...
(Date:11/19/2015)... 2015  Based on its in-depth analysis of the ... with the 2015 Global Frost & Sullivan Award for ... presents this award to the company that has developed ... of the market it serves. The award recognizes the ... on customer base demands, the overall impact it has ...
Breaking Biology News(10 mins):